Back

A shorter duration of dual-antiplatelet therapy for percutaneous coronary intervention following acute coronary syndrome: a meta-analysis of randomized clinical trials

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Antithrombotic therapy in acute coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Srikiran Dasari

Indiana University, Bloomington (United States of America)

7 More presentations in this session

Presentation thumbnail
Prognostic role of PRECISE-DAPT score in acute coronary syndrome: insight from sigle centre registry
Doctor D. Bauer (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Anticoagulation for treatment of left ventricular thrombus: an systematic review and meta-analysis
Doctor I. Schmal (Lucerne, CH)
Abstract Slides Video
Presentation thumbnail
Impact of pretreatment with P2Y12 receptor inhibitors on type 4a myocardial infarction and bleeding in patients with non-ST-segment elevation myocardial infarction: a propensity score matching study
Doctor N. Vasumini (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Effect of P2Y12 pretreatment on angiographic findings and in-hospital mortality in patients with ST-elevation myocardial infarction
Doctor N. Vythoulkas-Biotis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
CYP2C19 genetic variants and coronary atherosclerosis: insights beyond antiplatelet therapy
Doctor S. Chiusolo (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Antithrombotic therapy in acute coronary syndromes

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Dual antiplatelet therapy de-escalation followed by aspirin or P2Y12 inhibitor monotherapy after PCI for acute coronary syndrome: a systematic review and meta-analysis
thumbnail
Congress Presentation
A meta-analysis on the efficacy of ticagrelor monotherapy after 3 months of dual antiplatelet therapy vs ticagrelor plus aspirin dual therapy on patients with ACS who underwent PCI
thumbnail
Congress Presentation
Shortened versus standard duration of dual antiplatelet treatment after percutaneous coronary intervention in patients with and without chronic kidney disease: a systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources